Back to mobile site

Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)

October 30, 2024 6:10 AM EDT Send to a Friend
Goldman Sachs analyst Corinne Jenkins reiterated a Sell rating and $28.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login